Paul Bisaro Buys 2,000 Shares of Zoetis (NYSE:ZTS) Stock

Zoetis Inc. (NYSE:ZTS) Director Paul Bisaro purchased 2,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Zoetis Stock Down 3.4%

Shares of NYSE:ZTS traded down $2.62 during trading on Wednesday, reaching $74.32. 12,798,779 shares of the stock traded hands, compared to its average volume of 4,968,654. The stock has a 50-day moving average of $115.42 and a two-hundred day moving average of $122.28. Zoetis Inc. has a 52-week low of $74.29 and a 52-week high of $172.23. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The stock has a market cap of $31.16 billion, a P/E ratio of 12.33, a price-to-earnings-growth ratio of 1.25 and a beta of 0.87.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. During the same quarter in the previous year, the company earned $1.48 EPS. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 6.9 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Bank of America raised their target price on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, February 13th. Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Piper Sandler restated a “neutral” rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Stifel Nicolaus set a $105.00 target price on shares of Zoetis in a report on Friday, May 8th. Finally, William Blair restated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $141.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ZTS. Global Wealth Strategies & Associates purchased a new position in shares of Zoetis during the 4th quarter worth $25,000. Prosperity Bancshares Inc purchased a new position in shares of Zoetis during the 4th quarter worth $25,000. Cassaday & Co Wealth Management LLC purchased a new position in shares of Zoetis during the 1st quarter worth $28,000. Lodestone Wealth Management LLC purchased a new position in shares of Zoetis during the 4th quarter worth $30,000. Finally, Root Financial Partners LLC boosted its stake in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after acquiring an additional 103 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.